Translation-targeting therapeutics and methods for treating type-1 diabetes

The administration of G9a and Ezh2 inhibitors targets the translation of T1D-related proteins in pathogenic effector T cells, effectively addressing the autoimmune destruction of β-cells in Type-1 diabetes, providing a mechanism to prevent and reverse the disease with reduced toxicity.

WO2024238452A1PCT designated stage expired Publication Date: 2024-11-21THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/029064
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for Type-1 diabetes primarily focus on alleviating symptoms rather than preventing or reversing the disease, and there is a significant need for effective therapeutic compositions and methods to address the autoimmune destruction of insulin-secreting β-cells in pancreatic islets.

Method used

Administering a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, or combinations thereof, to mitigate cell autoimmunity by suppressing the translation of T1D-related proteins in pathogenic effector T cells, thereby reducing pancreas-infiltrating Teff and targeting aberrantly activated translation mechanisms in pathogenic effector T cells.

Benefits of technology

This approach effectively suppresses β cell autoimmunity, preventing and potentially reversing Type-1 diabetes by specifically targeting translation mechanisms in autoreactive Teff cells, offering a novel and less toxic strategy compared to conventional immunomodulatory therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024029064_21112024_PF_FP_ABST
    Figure US2024029064_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are methods of treating and / or preventing Type-1 diabetes (T1D) in a subject. Such methods include administering to the subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. Methods of regulating translation of proteins driving Teff-mediated β cell autoimmunity in vivo are also provided. Methods of identifying a compound to treat and / or prevent Type-1 diabetes (T1D) or related condition in a subject, including identifying a compound that blocks G9a translational regulation of β cell autoimmunity, are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No. 4210.0538WO TRANSLATION-TARGETING THERAPEUTICS AND METHODS FOR TREATING TYPE-1 DIABETES CROSS-REFERENCE TO RELATED APPLICATIONS This application claims benefit of U.S. Provisional Patent Application Serial No 63 / 466,031, filed May 12, 2023, which is herein incorporated by reference in its entirety. TECHNICAL FIELD The presently disclosed subject matter is directed to translation-targeting therapeutics and methods for treating Type-1 diabetes. More particularly, the presently disclosed subject matter is directed to methods of treating and / or preventing Type-1 diabetes by administering a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. GRANT STATEMENT This invention was made with government support under Grant Numbers DK133051, AG071229, and GM133107 awarded by the National Institutes of Health. The government has certain rights in the invention. BACKGROUND Type-1 diabetes (T1D) is a chronic autoimmune disease in which insulin- secreting β-cells are destroyed by immune cells that infiltrate the pancreatic islets (i.e., insulitis). Instead of preventing or reversing T1D, most treatments focus on alleviating symptoms with insulin-replacement therapy. Meanwhile, T1D is a heterogeneous disease that poses significant challenges to define mechanisms of pathogenesis and ultimately develop effective therapeutics. A significant need remains for effective therapeutic compositions and methods to treat and prevent T1D.Docket No. 4210.0538WO BRIEF SUMMARY This summary lists several embodiments of the presently disclosed subject matter, and in many cases lists variations and permutations of these embodiments. This summary is merely exemplary of the numerous and varied embodiments. The mention of one or more representative features of a given embodiment is likewise exemplary. Such an embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to other embodiments of the presently disclosed subject matter, whether listed in this summary or not. To avoid excessive repetition, this Summary does not list or suggest all possible combinations of such features. In one aspect, provided is a method of treating and / or preventing Type-1 diabetes (T1D) in a subject, the method includes administering to the subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. The method may also include where administration of the inhibitor mitigates cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells. The method may also include where G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive cell autoimmunity. The method may also include where β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff). The method may also include where the subject is suffering from T1D or susceptible to developing T1D. The method may also include where the G9a inhibitor includes a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a. The method may also include where the subject is co- administered both the inhibitor of G9a and the inhibitor of Ezh2. The method may also include where the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier. The method may also include where the subject is a human subject. In another aspect, a method of regulating translation of proteins driving Teff- mediated cell autoimmunity in vivo is provided, the method includes administering to subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. The method may also include where administration ofDocket No. 4210.0538WO the inhibitor mitigates cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells. The method may also include where G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive cell autoimmunity. The method may also include where β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff). The method may also include where G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation. The method may also include where the subject is suffering from T1D or susceptible to developing T1D. The method may also include where the G9a inhibitor includes a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a. The method may also include where the subject is co- administered both the inhibitor of G9a and the inhibitor of Ezh2. The method may also include where the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier. The method may also include where the subject is a human subject. In yet another aspect, a method of identifying a compound to treat and / or prevent Type-1 diabetes (T1D) or related condition in a subject is provided, the method includes identifying a compound that blocks G9a translational regulation of cell autoimmunity. The method may also include where the compound that blocks G9a translational regulation of cell autoimmunity does so by suppressing translation of T1D-related proteins in pathogenic effector T cells. The method may also include where the compound includes an inhibitor of G9a, optionally a small molecule inhibitor. The method may also include where the compound includes an inhibitor of Ezh2, optionally a small molecule inhibitor. The method may also include where G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation. The method may also include where targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1DDocket No. 4210.0538WO progression. The method may also include where the G9a inhibitor includes UNC0642. The method may also include where the EZH2 inhibitor includes UNC1999. The method may also include where targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1D progression. The method may also include where the G9a inhibitor includes UNC0642. The method may also include where the EZH2 inhibitor includes UNC1999. In yet another aspect, provided is the use of a composition for treating a subject suffering from symptoms of Type-1 diabetes (T1D) or related condition, includes administering to the subject the composition includes a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. The use may also include where administration of the inhibitor mitigates cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells. The use may also include where G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive cell autoimmunity. The use may also include where β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff). The use may also include where G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation. The use may also include where the subject is suffering from T1D or susceptible to developing T1D. The use may also include where the G9a inhibitor includes a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a. The use may also include where the subject is co-administered both the inhibitor of G9a and the inhibitor of Ezh2. The use may also include where the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier. The use may also include where the subject is a human subject. The use may also include where targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1D progression. The useDocket No. 4210.0538WO may also include where the G9a inhibitor includes UNC0642. The use may also include where the EZH2 inhibitor includes UNC1999. Other technical features and embodiments may be readily apparent to one skilled in the art from the following figures, descriptions, and claims. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS The presently disclosed subject matter can be better understood by referring to the following figures. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the presently disclosed subject matter (often schematically). In the figures, like reference numerals designate corresponding parts throughout the different views. A further understanding of the presently disclosed subject matter can be obtained by reference to an embodiment set forth in the illustrations of the accompanying drawings. Although the illustrated embodiment is merely exemplary of systems for carrying out the presently disclosed subject matter, both the organization and method of operation of the presently disclosed subject matter, in general, together with further objectives and advantages thereof, may be more easily understood by reference to the drawings and the following description. The drawings are not intended to limit the scope of this presently disclosed subject matter, which is set forth with particularity in the claims as appended or as subsequently amended, but merely to clarify and exemplify the presently disclosed subject matter. For a more complete understanding of the presently disclosed subject matter, reference is now made to the following figures. FIGS.1A and 1B show the data from experiments to test the in vivo effects of inhibiting the enzymatic activity of G9a and Ezh2 on β cell-specific T cell reactivity. FIG. 2 is a schematic illustration of quantitative proteomic and phosphoproteomic experiments demonstrating that G9a and Ezh2 treatment reduced islet T cell numbers and that these proteins are functionally associated with multiple pathways including lymphocyte (T cell activation / proliferation), Myc-Docket No. 4210.0538WO mediated glucose metabolism in diabetes, ChREBP-β (MLXIPL)-mediated pancreatic disease pathways, and IL-6 signaling. FIGS. 3A-3D show results of pulse AACT proteomic analysis of G9a- upregulated protein synthesis. (3A) Pulsed AACT / SILAC ex vivo culture with or without UNC0642 treatment; (3B) MS spectra of time-dependent AACT incorporation; (3C) AACT quantitation of peptides that showed G9a inhibitor (UNC0642) treatment changes; (3D) Equations to calculate the UNC0642-affected rates of protein synthesis. DETAILED DESCRIPTION The presently disclosed subject matter now will be described more fully hereinafter, in which some, but not all embodiments of the presently disclosed subject matter are described. Indeed, the presently disclosed subject matter can be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. I. General Definitions The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the presently disclosed subject matter. While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter. All technical and scientific terms used herein, unless otherwise defined below, are intended to have the same meaning as commonly understood by one of ordinary skill in the art. References to techniques employed herein are intended to refer to the techniques as commonly understood in the art, including variations on those techniques or substitutions of equivalent techniques that would be apparent to one of skill in the art. While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter.Docket No. 4210.0538WO In describing the presently disclosed subject matter, it will be understood that a number of techniques and steps are disclosed. Each of these has individual benefit and each can also be used in conjunction with one or more, or in some cases all, of the other disclosed techniques. Accordingly, for the sake of clarity, this description will refrain from repeating every possible combination of the individual steps in an unnecessary fashion. Nevertheless, the specification and claims should be read with the understanding that such combinations are entirely within the scope of the invention and the claims. Following long-standing patent law convention, the terms “a”, “an”, and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so forth. Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter. As used herein, the term “about,” when referring to a value or to an amount of a composition, dose, sequence identity (e.g., when comparing two or more nucleotide or amino acid sequences), mass, weight, temperature, time, volume, concentration, percentage, etc., is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions. The term “comprising”, which is synonymous with “including” “containing” or “characterized by” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. “Comprising” is a term of art used in claim language which means that the named elements are essential, but other elements can be added and still form a construct within the scope of the claim. As used herein, the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. When the phrase “consists of” appears in aDocket No. 4210.0538WO clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole. As used herein, the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps, plus those that do not materially affect the basic and novel characteristic(s) of the claimed subject matter. With respect to the terms “comprising”, “consisting of”, and “consisting essentially of”, where one of these three terms is used herein, the presently disclosed and claimed subject matter can include the use of either of the other two terms. As used herein, the term “and / or” when used in the context of a listing of entities, refers to the entities being present singly or in combination. Thus, for example, the phrase “A, B, C, and / or D” includes A, B, C, and D individually, but also includes any and all combinations and subcombinations of A, B, C, and D. The term “gene” refers broadly to any segment of DNA associated with a biological function. A gene can comprise sequences including but not limited to a coding sequence, a promoter region, a cis-regulatory sequence, a non-expressed DNA segment that is a specific recognition sequence for regulatory proteins, a non- expressed DNA segment that contributes to gene expression, a DNA segment designed to have desired parameters, or combinations thereof. A gene can be obtained by a variety of methods, including cloning from a biological sample, synthesis based on known or predicted sequence information, and recombinant derivation of an existing sequence. As is understood in the art, a gene comprises a coding strand and a non-coding strand. As used herein, the terms “coding strand”, “coding sequence” and “sense strand” are used interchangeably, and refer to a nucleic acid sequence that has the same sequence of nucleotides as an mRNA from which the gene product is translated. As is also understood in the art, when the coding strand and / or sense strand is used to refer to a DNA molecule, the coding / sense strand includes thymidine residues instead of the uridine residues found in the corresponding mRNA. Additionally, when used to refer to a DNA molecule, the coding / sense strand can also include additional elements not found in the mRNA including, but not limited to promoters, enhancers, and introns. Similarly, the terms “template strand” and “antisense strand” are usedDocket No. 4210.0538WO interchangeably and refer to a nucleic acid sequence that is complementary to the coding / sense strand. Similarly, all genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable. Thus, the terms include, but are not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates. Also encompassed are any and all nucleotide sequences that encode the disclosed amino acid sequences, including but not limited to those disclosed in the corresponding GENBANK® entries. The term “gene expression” generally refers to the cellular processes by which a biologically active polypeptide is produced from a DNA sequence and exhibits a biological activity in a cell. As such, gene expression involves the processes of transcription and translation, but also involves post-transcriptional and post- translational processes that can influence a biological activity of a gene or gene product. These processes include, but are not limited to RNA syntheses, processing, and transport, as well as polypeptide synthesis, transport, and post-translational modification of polypeptides. Additionally, processes that affect protein-protein interactions within the cell can also affect gene expression as defined herein. The terms "modulate" or “alter” are used interchangeably and refer to a change in the expression level of a gene, or a level of RNA molecule or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the absence of the modulator. For example, the terms "modulate" and / or “alter” can mean "inhibit" or “suppress”, but the use of the words "modulate" and / or “alter” are not limited to this definition. As used herein, the terms "inhibit", “suppress”, “repress”, “downregulate”, “loss of function", “block of function", and grammatical variants thereof are used interchangeably and refer to an activity whereby gene expression (e.g., a level of an RNA encoding one or more gene products) and / or translation (e.g. the production of proteins or gene products based on the information stored in the RNA) is reducedDocket No. 4210.0538WO below that observed in the absence of a composition of the presently disclosed subject matter. In some embodiments, inhibition results in a decrease in the translation of gene products involved in T1D. The term "RNA" refers to a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" is meant a nucleotide with a hydroxyl group at the 2' position of a D-ribofuranose moiety. The terms encompass double stranded RNA, single stranded RNA, RNAs with both double stranded and single stranded regions, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA, or analog RNA, that differs from naturally occurring RNA by the addition, deletion, substitution, and / or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the presently disclosed subject matter can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of a naturally occurring RNA. “Transcription” and “translation” are processes a cell uses to make all proteins the body needs to function from information stored in the sequence of bases in DNA. The four bases (C, A, T / U, and G in the figure) are the building blocks of DNA and RNA. During transcription, a piece of DNA that codes for a specific gene is copied into messenger RNA (mRNA) in the nucleus of the cell. The mRNA then carries the genetic information from the DNA to the cytoplasm, where translation occurs. During translation, proteins are made using the information stored in the mRNA sequence. The mRNA attaches to a structure called a ribosome that can read the genetic information. As the mRNA passes through the ribosome, another type of RNA called transfer RNA (tRNA) carries a protein building block called an amino acid to the ribosome. The tRNA carrying the amino acid binds to a matching sequence in the mRNA. As each tRNA binds to the mRNA strand, the amino acid it carried joins with the other amino acids to form a chain of amino acids. Once all of the amino acids coded for in the piece of mRNA have been linked, the completed protein is released from the ribosome. As discussed herein, these “transcription” and / or “translation” processes, particularly with respect to T1D-related pathways an associatedDocket No. 4210.0538WO components, e.g. G9a and Ezh2, can be targeted, disrupted and / or modulated in the treatment or prevention of T1D. As used herein, the terms “detectable moiety”, “detectable label”, and “detectable agent” refer to any molecule that can be detected by any moiety that can be added to a chemoprobe, antigen, inhibitor, marker, reagent and / or antibody, or a fragment or derivative thereof, that allows for the detection of the chemoprobe, antigen, inhibitor, marker, reagent and / or antibody, fragment, or derivative in vitro and / or in vivo. Representative detectable moieties include, but are not limited to, chromophores, fluorescent moieties, radioacite labels, affinity probes, enzymes, antigens, groups with specific reactivity, chemiluminescent moieties, and electrochemically detectable moieties, etc. In some embodiments, the antibodies are biotinylated. As used herein, an “effective amount” or “therapeutically effective amount” refers to an amount of a compound or composition sufficient to produce a selected effect, such as but not limited to alleviating symptoms of a condition, disease, or disorder. In the context of administering compounds in the form of a combination, such as multiple compounds, the amount of each compound, when administered in combination with one or more other compounds, may be different from when that compound is administered alone. Thus, an effective amount of a combination of compounds refers collectively to the combination as a whole, although the actual amounts of each compound may vary. The term “more effective” means that the selected effect occurs to a greater extent by one treatment relative to the second treatment to which it is being compared. II. Pharmaceutical Compositions The disclosure provides a pharmaceutical composition for use in the treatment of the diseases and conditions described herein. In some embodiments, the disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a component sufficient to treating and / or preventing Type-1 diabetes (T1D). The pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. Typically, the pharmaceutical compositions also compriseDocket No. 4210.0538WO one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. In some embodiments, the concentration of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof provided in the pharmaceutical compositions of the disclosure is less than, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w / w, w / v or v / v of the pharmaceutical composition. In some embodiments, the concentration of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof provided in the pharmaceutical compositions of the disclosure is independently greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25% 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w / w, w / v, or v / v of the pharmaceutical composition. In some embodiments, the concentration of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof provided in the pharmaceutical compositions of the disclosure is in the range from about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 30%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 23%, about 0.09%Docket No. 4210.0538WO to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12% or about 1% to about 10% w / w, w / v or v / v of the pharmaceutical composition. In some embodiments, the concentration of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof provided in the pharmaceutical compositions of the disclosure is in the range from about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1%, about 0.1% to about 0.9% w / w, w / v or v / v of the pharmaceutical composition. In some embodiments, the amount of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof provided in the pharmaceutical compositions of the disclosure is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g. In some embodiments, the amount of any one of the pharmaceutical compositions of the disclosure is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5 g, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g. Each of the compounds provided according to the disclosure is effective over a wide dosage range. For example, in the treatment of adult humans, dosagesDocket No. 4210.0538WO independently ranging from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the gender and age of the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician. Described below are non-limiting pharmaceutical compositions and methods for preparing the same. i. Pharmaceutical Compositions for Oral Administration In preferred embodiments, the disclosure provides a pharmaceutical composition for oral administration containing inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof and their features and limitations as described herein, or pharmaceutically acceptable analogs, derivatives, salts, solvates, hydrates, cocrystals, or prodrugs thereof, described herein, and a pharmaceutical excipient suitable for administration. In preferred embodiments, the disclosure provides a solid pharmaceutical composition for oral administration containing an inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof and their features and limitations as described herein, or pharmaceutically acceptable analogs, derivatives, salts, solvates, hydrates, cocrystals, or prodrugs thereof, and a pharmaceutical excipient suitable for administration. In some embodiments, the composition further contains an effective amount of an additional active pharmaceutical ingredient. Such additional active pharmaceutical ingredients may also include those compounds used for sensitizing cells to additional agent(s). In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the disclosure suitable for oral administration can be presented as discrete dosage forms, such as capsules, sachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, a water-in-oil liquid emulsion, powders for reconstitution, powders for oral consumptions, bottles (including powders or liquids in a bottle), orally dissolvingDocket No. 4210.0538WO films, lozenges, pastes, tubes, gums, and packs. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient(s) into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient(s) with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and / or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The disclosure further encompasses anhydrous pharmaceutical compositions and dosage forms since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the disclosure can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the disclosure which contain lactose can be made anhydrous if substantial contact with moisture and / or humidity during manufacturing, packaging, and / or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs. Active pharmaceutical ingredients can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms dependingDocket No. 4210.0538WO on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof. Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. Disintegrants may be used in the compositions of the disclosure to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which disintegrate in the bottle. Too little may be insufficient for disintegration to occur, thus altering the rate and extent of release of the active ingredients from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to thoseDocket No. 4210.0538WO of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about I to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof. Lubricants which can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, calcium stearate, magnesium stearate, sodium stearyl fumarate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethylaureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, silicified microcrystalline cellulose, or mixtures thereof. A lubricant can optionally be added in an amount of less than about 0.5% or less than about 1% (by weight) of the pharmaceutical composition. When aqueous suspensions and / or elixirs are desired for oral administration, the active pharmaceutical ingredient(s) may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and / or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof. The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.Docket No. 4210.0538WO Surfactants which can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed. A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non ionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions. Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions. Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyllactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof. Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts;Docket No. 4210.0538WO sodium docusate; acyllactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof. Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citric acid esters of mono / diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof. Hydrophilic non-ionic surfactants may include, but not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene- polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.Docket No. 4210.0538WO Other hydrophilic-non-ionic surfactants include, without limitation, PEG- IO laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG- 15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate / caprylate glycerides, PEG-8 caprate / caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-IO oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-I 00 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG I 0-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers. Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil soluble vitamins / vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

[0163] In an embodiment, the composition may include a solubilizer to ensure good solubilization and / or dissolution of the compound ofDocket No. 4210.0538WO the present disclosure and to minimize precipitation of the compound of the present disclosure. This can be especially important for compositions for non-oral use - e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and / or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion. Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds such as 2- pyrrolidone, 2-piperidone, E-caprolactam, N-alky1pyrrolidone, N-hydroxyalky 1pyrrolidone, N-alky1piperidone, N-alky1caprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, .epsilon. caprolactone and isomers thereof, 8-valerolactone and isomers thereof, -butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water. Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N- methylpyrrolidone, N-hydroxyethy1pyrrolidone, polyviny1pyrrolidone, hydroxypropy1 methy1cellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol. The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, itDocket No. 4210.0538WO may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a patient using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%, 50%, 100%, or up to about 200% by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%, 2%, 1% or even less. Typically, the solubilizer may be present in an amount of about 1% to about 100%, more typically about 5% to about 25% by weight. The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof. In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphateDocket No. 4210.0538WO can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals and alkaline earth metals. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium. Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid and uric acid. ii. Pharmaceutical Compositions for Injection In preferred embodiments, the disclosure provides a pharmaceutical composition for injection containing an inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof and a pharmaceutical excipient suitable for injection. Components and amounts of compounds in the compositions are as described herein. The forms in which the compositions of the disclosure may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol and liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and thimerosal.Docket No. 4210.0538WO Sterile injectable solutions are prepared by incorporating inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof in the required amounts in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. iii. Pharmaceutical Compositions for Topical Delivery In preferred embodiments, the disclosure provides a pharmaceutical composition for transdermal delivery containing an inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof and a pharmaceutical excipient suitable for transdermal delivery. Compositions of the present disclosure can be formulated into preparations in solid, semi-solid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area. The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration-enhancing molecules known to those trained in the art of topical formulation. Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes,Docket No. 4210.0538WO alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Another exemplary formulation for use in the methods of the present disclosure employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof in controlled amounts, either with or without another active pharmaceutical ingredient. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252; 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. iv. Pharmaceutical Compositions for Inhalation Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner. Dry powder inhalers may also be used to provide inhaled delivery of the compositions. v. Other Pharmaceutical Compositions Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, et al., eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; and Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, N.Y., 1990, each of which is incorporated by reference herein in its entirety.Docket No. 4210.0538WO The disclosure also provides kits. The kits include an inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof in suitable packaging, and written material that can include instructions for use, discussion of clinical studies and listing of side effects. Such kits may also include information, such as scientific literature references, package insert materials, clinical trial results, and / or summaries of these and the like, which indicate or establish the activities and / or advantages of the composition, and / or which describe dosing, administration, side effects, drug interactions, or other information useful to the health care provider. Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. The kit may further contain another active pharmaceutical ingredient. Suitable packaging and additional articles for use (e.g., measuring cup for liquid preparations, foil wrapping to minimize exposure to air, and the like) are known in the art and may be included in the kit. Kits described herein can be provided, marketed and / or promoted to health providers, including physicians, nurses, pharmacists, formulary officials, and the like. Kits may also, in some embodiments, be marketed directly to the consumer. The kits described above are preferably for use in the treatment of the diseases and conditions described herein. In a preferred embodiment, the kits are for use in the treatment of cancer or hyperproliferative disorders. In an embodiment, the kits described herein are for use in the treatment of T1D. vi. Dosages and Dosing Regimens The amounts of inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof administered, will be dependent on the human or mammal being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compounds and the discretion of the prescribing physician. However, an effective dosage of each is in the range of about 0.001 to about 100 mg per kg body weight per day, such as about 1 to about 35 mg / kg / day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g / day, such as about 0.05 to about 2.5 g / day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect - e.g., byDocket No. 4210.0538WO dividing such larger doses into several small doses for administration throughout the day. The dosage may be provided in units of mg / kg of body mass or in mg / m2of body surface area. In some embodiments, dosing may be once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be once a month, once every two weeks, once a week, or once every other day. In some embodiments, inhibitor of G9a, inhibitor of Ezh2, and / or combinations thereof is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, 7Bi or variant thereof is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In yet another embodiment, the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary. In some embodiments, an effective dosage is in the range of about 1 mg to about 500 mg, about 10 mg to about 300 mg, about 20 mg to about 250 mg, about 25 mg to about 200 mg, about 10 mg to about 200 mg, about 20 mg to about 150 mg, about 30 mg to about 120 mg, about 10 mg to about 90 mg, about 20 mg to about 80 mg, about 30 mg to about 70 mg, about 40 mg to about 60 mg, about 45 mg to about 55 mg, about 48 mg to about 52 mg, about 50 mg to about 150 mg, about 60 mg to about 140 mg, about 70 mg to about 130 mg, about 80 mg to about 120 mg, about 90 mg to about 110 mg, about 95 mg to about 105 mg, about 150 mg to about 250 mg, about 160 mg to about 240 mg, about 170 mg to about 230 mg, about 180 mg to about 220 mg, about 190 mg to about 210 mg, about 195 mg to about 205 mg, or about 198 to about 202 mg. In some embodiments, an effective dosage is in the range of about 0.01 mg / kg to about 4.3 mg / kg, about 0.15 mg / kg to about 3.6 mg / kg, about 0.3 mg / kg to about 3.2 mg / kg, about 0.35 mg / kg to about 2.85 mg / kg, about 0.15 mg / kg to about 2.85 mg / kg, about 0.3 mg to about 2.15 mg / kg, about 0.45 mg / kg to about 1.7 mg / kg, about 0.15 mg / kg to about 1.3 mg / kg, about 0.3 mg / kg to about 1.15 mg / kg, about 0.45 mg / kg to about 1 mg / kg, about 0.55 mg / kg to about 0.85 mg / kg, about 0.65 mg / kg to about 0.8 mg / kg, about 0.7 mg / kg to about 0.75 mg / kg, about 0.7 mg / kg to about 2.15 mg / kg, about 0.85 mg / kg to about 2 mg / kg, about 1 mg / kg to about 1.85 mg / kg, about 1.15 mg / kg to about 1.7 mg / kg, about 1.3 mg / kg mg to about 1.6 mg / kg, about 1.35 mg / kg to about 1.5 mg / kg, about 2.15 mg / kg toDocket No. 4210.0538WO about 3.6 mg / kg, about 2.3 mg / kg to about 3.4 mg / kg, about 2.4 mg / kg to about 3.3 mg / kg, about 2.6 mg / kg to about 3.15 mg / kg, about 2.7 mg / kg to about 3 mg / kg, about 2.8 mg / kg to about 3 mg / kg, or about 2.85 mg / kg to about 2.95 mg / kg. In some instances, dosage levels below the lower limit of the aforesaid ranges may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect - e.g., by dividing such larger doses into several small doses for administration throughout the day. An effective amount may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant. III. Subjects The subject treated, screened, tested, or to which a dosage is administered, is desirably a human subject, although it is to be understood that the principles of the disclosed subject matter indicate that the compositions and methods are effective with respect to invertebrate and to all vertebrate species, including mammals, which are intended to be included in the term “subject”. Moreover, a mammal is understood to include any mammalian species in which screening is desirable, particularly agricultural and domestic mammalian species. The disclosed methods, treatments and uses are particularly useful in the treatment of warm-blooded vertebrates. Thus, the presently disclosed subject matter concerns mammals and birds. In some embodiments, the subject to be used in accordance with the presently disclosed subject matter is a subject in need of treatment and / or diagnosis. In some embodiments, a subject can have or be believed to be suffering from T1D or related conditions or phenotype, and / or believed to be susceptible to developing T1D. IV. Translation-targeting therapeutics and methods for treating Type I DiabetesDocket No. 4210.0538WO Current treatment of type-1 diabetes (T1D) focuses on alleviating symptoms instead of preventing or reversing T1D. As a heterogeneous disease, T1D poses significant challenges to define mechanisms of pathogenesis and to develop effective therapeutics. Using a chromatin-activity-based chemoproteomics (ChaC) approach (Liu et al., 2014) to dissect T1D heterogeneity, particular T1D-related pathways associated with G9a (EHMT2), a histone methyltransferase, were identified. Small molecule inhibition of G9a enzymatic activity, in nonobese diabetic (NOD) mice, a well-established T1D model, specifically mitigated β cell autoimmunity. Accordingly, the mechanism of inhibitor action wherein inhibition of the aberrantly activated G9a suppressed the translation (synthesis) of T1D-related proteins in pathogenic effector T cells (Teff) that infiltrate (insulitis) pancreatic islets was deciphered. Based on these compelling and surprising data, a new generation of mechanism-based, Teff-specific therapeutics of early-stage T1D were developed, as disclosed herein. T1D is caused by pancreatic islet Teff insulitis that destroy insulin-secreting β-cells. There is no established clinical approach to suppress ongoing β cell autoimmunity specifically and effectively. This inability to reverse autoimmunity is due partly to a poor understanding of the mechanisms that initiate and drive insulitis. Because epidemiologic evidence showed that G9a is constitutively activated in lymphocytes from T1D patients, the ChaC approach as used with a biotinylated G9a inhibitor that specifically binds to the active form of G9a (Wrobel et al.) to dissect the pathways and mechanisms of T1D pathogenesis. In both splenocytes of NOD mice that had highly infiltrated islets and in peripheral blood mononuclear cells (PBMCs) of T1D patients, ChaC technology captured and identified the same translation regulatory proteins that interact with G9a, revealing a mouse-to-human conserved, G9a-interacting, translational mechanism of T1D pathogenesis. Accordingly, it was discovered that targeting this translational mechanism by G9a inhibition or inhibition of a ChaC-identified G9a-interactor Ezh2 in NOD mice selectively reduced pancreas- infiltrating Teff that drive β cell autoimmunity. Further, in correlation with the inhibitor reduction of Teff cells in T1D mice, these quantitative proteomic results indicated that G9a inhibition reversed the broad landscape of Teff proteome that recaptured the symptomatic T1D-related proteome.Docket No. 4210.0538WO Importantly, this mouse-to-human conservation of inhibitor-affected T1D proteome that represents clinical T1D pathology indicated that suppressing G9a- mediated, protein-specific translation in Teff cells is clinically practical for effective therapeutics of T1D. Notably, there is a strong rationale to modulate the synthesis of T1D-driving proteins as a Teff-specific therapeutic approach because proteins directly mediate events that promote pathogenicity, and inhibiting protein synthesis occurs on a much faster timescale compared with gene transcription. Thus, targeting G9a- mediated translational mechanisms in autoreactive Teff is a Teff-specific, effective, and less toxic strategy to prevent and / or reverse T1D. Because G9a / Ezh2 inhibitors specifically bind to their Teff-active (or overactive) forms, not their abundances, that promote the progression of T1D, these inhibitors can target Teff with greater specificity compared with other cell types. Thus, the inhibitors will have low toxicity (off-targets) toward other organs. This mechanistic discovery that G9a and Ezh2 regulate translation of proteins that drive Teff-mediated β cell autoimmunity provides a novel translation-targeting approach to treat T1D. Because translational regulation is the precise and energy-efficient step of controlling the ultimate expression of proteins, inhibiting this translation regulatory mechanism can immediately suppress the aberrant synthesis of pathogenic proteins. In contrast to conventional immunomodulatory therapies that typically target a single cytokine, chemokine, surface molecule, inhibiting G9a or Ezh2 activity modulates a range of proteins that regulate the expansion and function of β cell-specific Teff, which, in turn, will enhance the efficacy of T1D prevention and reversal with low toxicity. This is a remarkable improvement over existing approaches and solves a long-felt need. Thus, in one aspect, provided are methods of treating and / or preventing Type- 1 diabetes (T1D) in subjects. Such methods includes administering to a subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. More particularly, in some embodiments, such methods also include where administration of the inhibitor mitigates cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells. In some aspects, translation of T1D-related proteins in pathogenic effector T cells can be suppressed by about 5%, about 10%, about 20%, about 30%, about 40%, aboutDocket No. 4210.0538WO 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or more, optionally about 5% to about 25%, about 25% to about 50%, or about 50% or more. G9a inhibition or inhibition of Ezh2 can also reduce pancreas-infiltrating Teff that drive cell autoimmunity. More specifically, and as demonstrated by the data herein, such methods may also include where β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff). In some embodiments, β cell autoimmunity can be suppressed by about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or more, optionally by about 5% to about 25%, about 25% to about 50%, or about 50% or more. These methods may also include where the subject to be treated and / or administered the disclosed inhibitors is suffering from T1D or susceptible to developing T1D. The methods may also include where the subject is a human subject. The G9a inhibitor includes a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a. Such methods may also include where the subject is co-administered both the inhibitor of G9a and the inhibitor of Ezh2. The inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier. Any suitable route of administration is within the scope of this disclosure, including for example those routes of administrations disclosed and discussed herein. As disclosed herein, such methods can include the use of any inhibitor of G9a and / or Ezh2. By way of example and not limitation, the G9a inhibitor includes UNC0642. By way of example and not limitation, the EZH2 inhibitor includes UNC1999. UNC0642 is a small molecule inhibitor, in some aspects referred to as a G9a histone methyltransferase inhibitor, and includes the following chemical structure:Docket No. 4210.0538WO .name difluoropiperidin-1-yl)-N-(1- isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4- amine. The molecular formula for UNC0642 is C29H44F2N6O2, and the CAS number is 1481677-78-4. UNC1999 is a small molecule inhibitor, in some aspects referred to as a selective, cell-permeable EZH2 inhibitor, with a chemical structure shown as follows: .The formal name for UNC1999 is N-[(1,2-dihydro-6-methyl-2-oxo-4-propyl- 3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-[4-(1-methylethyl)-1-piperazinyl]-3-1H- indazole-4-carboxamide. The molecular formula for UNC1999 is C33H43N7O2, and the CAS number is 1431612-23-5. Also provided herein are methods of regulating the translation of proteins driving Teff-mediated cell autoimmunity in vivo, particularly as it relates to the development of T1D in subjects. Such methods include administering to a subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / orDocket No. 4210.0538WO combinations thereof. By administering the inhibitor(s) cell autoimmunity can be mitigated by suppressing translation of T1D-related proteins in pathogenic effector T cells. In some aspects, in such methods the G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive cell autoimmunity. Additionally, in some instances the method may also include where β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff). Moreover, the methods may also include where G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation. In some aspects, G9a and / or Ezh2 inhibition, by virtue of administration of one or more inhibitors herein, can be about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or more, optionally about 5% to about 25%, about 25% to about 50%, or about 50% or more. In some aspects, downregulation of in vivo expression of proteins regulating Teff pathogenicity can be about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or more, optionally about 5% to about 25%, about 25% to about 50%, or about 50% or more. Such methods may also include where the G9a inhibitor includes a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a. In some aspects, the subject can be co-administered both the inhibitor of G9a and the inhibitor of Ezh2. The inhibitor of G9a and / or Ezh2 can be administered to the subject in a pharmaceutically acceptable formulation or carrier. As disclosed herein, such methods can include the use of any inhibitor of G9a and / or Ezh2. By way of example and not limitation, the G9a inhibitor includes UNC0642. By way of example and not limitation, the EZH2 inhibitor includes UNC1999. Further details of each of UNC0642 and UNC1999 are provided herein. As with the other methods disclosed herein, such methods may also include where the subject is suffering from T1D or susceptible to developing T1D. Such subjects can include any subjects as disclosed herein, including human subjects.Docket No. 4210.0538WO Also provided herein are methods for identifying, screening for and / or developing a compound to treat and / or prevent T1D or related conditions in a subject. Such methods include identifying a compound that blocks G9a translational regulation of cell autoimmunity. Such methods may also include where the compound that blocks G9a translational regulation of cell autoimmunity does so by suppressing translation of T1D-related proteins in pathogenic effector T cells. Such methods may also include where the compound includes an inhibitor of G9a, optionally a small molecule inhibitor. The methods may also include where the compound includes an inhibitor of Ezh2, optionally a small molecule inhibitor. By way of example and not limitation, the G9a inhibitor includes UNC0642. By way of example and not limitation, the EZH2 inhibitor includes UNC1999. Further details of each of UNC0642 and UNC1999 are provided herein. The methods for identifying, screening for and / or developing a compound to treat and / or prevent T1D or related conditions in a subject may also include where G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation. Such methods may also include where targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1D progression. Correspondingly, uses of a composition for treating a subject suffering from symptoms of T1D or related condition are also provided. Such uses include administering to the subject a composition including a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof. By way of example and not limitation, the G9a inhibitor includes UNC0642. By way of example and not limitation, the EZH2 inhibitor includes UNC1999. Further details of each of UNC0642 and UNC1999 are provided herein. Such uses may also include where administration of the inhibitor mitigates cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells. The uses may also include where G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive cell autoimmunity. The uses may also include where β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff). The uses may also include where G9a and / or Ezh2Docket No. 4210.0538WO inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation. Such uses can in some embodiments include where the G9a inhibitor includes a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a. In such uses the subject can also be co-administered both the inhibitor of G9a and the inhibitor of Ezh2. The uses may also include where the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier. These uses may also include where the subject is suffering from T1D or susceptible to developing T1D. The uses may also include where the subject is a human subject V. EXAMPLES The following examples are included to further illustrate various embodiments of the presently disclosed subject matter. However, those of ordinary skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the presently disclosed subject matter. The examples below highlight key advances in (1) discovery of novel inhibitors of T1D-driving islet inflammation, (2) uses of affinity-tagged inhibitors of islet inflammation as probes for dissecting the mechanism of action of inhibitors on T1D pathogenesis, and (3) proteomic discovery of the inhibitor specificity in suppressing Teff-specific expression or phosphorylation of certain proteins associated with T1D etiology and pathogenesis. EXAMPLE 1 Novel G9a-upregulated translation mechanism in pathogenic effector T cells is a target to blunt β cell autoimmunity. Epidemiology shows that T1D onset is associated with the enzymatic activity of G9a (EHMT2) and G9a-like protein GLP; (herein G9a represents both proteins) in lymphocytes. Furthermore, it was discovered and disclosed herein that UNC0642Docket No. 4210.0538WO (Kim et al., 2017), a potent G9a inhibitor, suppressed β cell-specific Teff in NOD mice, a T1D model. The results provided herein strongly show that G9a-interacting pathways promote β cell autoimmunity and T1D pathogenesis. Correspondingly, using biotinylated UNC0965 (Konze et al., 2014), that specifically binds to enzymatically active G9a (IC50 < 2.5 nM), the G9a-associated pathways in T1D specimens were dissected using the Chromatin-activity-based Chemoproteomics (ChaC)-mass spectrometry (MS) technique (Liu et al., 2014). For reference, UNC0965 is a small molecule inhibitor with a chemical structure shown as follows: .The formal name for UNC0965 is N-(2-(2-(2-(2-(4-(3-(4-((2-Cyclohexyl-6- methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-yl)amino)piperidin-1- yl)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aR,4R,6aS)-2- oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, with the molecular formula of C50H79N11O7S. A T1D-characteristic profile of G9a interactors that showed the mouse-to- human conservation between NOD mice splenocytes and T1D patient PBMCs was identified. This conservation validated the T1D clinical correlation of G9a-interacting pathways. Furthermore, an inhibitor of Ezh2, a ChaC-identified G9a interactor similarly reduced islet-infiltrating Teff in NOD mice, confirming the pathologic activity of G9a interactome in T1D (see below). Importantly, proteomic analysis of the pancreatic CD4+ T cells from the NOD mice at diabetic stages revealed that G9a inhibition suppressed T1D-correlated overexpression of G9a-interacting translation regulators but also certain inflammatory proteins involved in β cell autoimmunity, such as IFN-γ, IL‐1β, and CXCL10. These results established a new, non-canonical G9a function of promoting translation of a battery of T1D pathogenesis-associatedDocket No. 4210.0538WO proteins. In sum, components of G9a-interacting translation regulatory pathways not only drive T1D immunopathology but also, they provide new drug targets for mitigating β cell autoimmunity. Thus, targeting G9a-mediated translational mechanisms in autoreactive Teff cells is an effective route to prevent or reverse T1D. EXAMPLE 2 Inhibitors of G9a and Ezh2 specifically and effectively suppress the pancreatic Teff cells. Although G9a and Ezh2 are ubiquitously expressed and essential for cell proliferation and differentiation, the activity of G9a was found by epidemiologic analysis to be aberrantly greater in the immune effector cells, such as Teff, associated with T1D progression. That is, it is constitutive activation of G9a, not G9a abundance, that promotes the progression of T1D. Because G9a / Ezh2 inhibitors specifically bind to the enzymatically active (or overactive) forms of G9a and Ezh2, the inhibitors can target Teff with greater specificity compared with other cell types; thus, the inhibitors will have low toxicity (off-targets) toward other organs. In addition, because translational regulation is the precise and energy-efficient step of controlling ultimate protein expression, inhibiting G9a-coordianted translation regulatory mechanism can immediately suppress the synthesis of widespread T1D- driving proteins. The scientific premise of this proposal is built on the discovery of G9a- associated translation regulatory mechanisms that underly β cell autoimmunity and which can be blocked by inhibitors of G9a and Ezh2, as disclosed herein. Like the epidemiologically observed Teff-specific activation of G9a, the data disclosed herein shows that G9a or Ezh2 inhibition in NOD mice specifically and effectively reduces pancreas-infiltrating Teff cells that drive β cell autoimmunity. These phenotypic and proteomic findings together clearly indicate the high inhibitor specificity in suppressing pathogenic Teff cells. The scientific rigor of this disclosure is exemplified by a ChaC-MS-defined profile of G9a interactors shared in murine and human T1D.Docket No. 4210.0538WO EXAMPLE 3 ChaC-MS identified a characteristic profile of G9a interactors associated with T1D immunopathology The specificity of immobilized UNC0965 in capturing G9a interactors linked to T1D was determined first. Label-free quantitation (LFQ) ChaC-MS experiments were performed on (1) splenocytes prepared from 12-week old NOD female mice and (2) human PBMCs from newly diagnosed T1D individuals. NOD mice aged 12 weeks represent a late preclinical stage of T1D in which animals are euglycemic but β cell autoimmunity (i.e., insulitis) is well established. Non-T1D controls were splenocytes from non-autoimmune C57BL / 6 (B6) mice and PBMCs from healthy donors. Human PBMCs are a mixture of immune effectors including lymphocytes (T cells, B cells) and monocytes (dendritic cells, macrophages). On the basis of LFQ ratios that represent the relative binding of individual proteins to enzymatically active G9a, 95 and 142 UNC0965-captured proteins were identified with statistically significant log2 LFQ ratios in NOD versus B6 mouse splenocytes and T1D versus healthy donor PBMCs, respectively. G9a interactors in NOD mouse splenocytes were clustered and well separated from G9a interactors in control B6 mouse splenocytes. Strikingly, it was found that greater than 60% of G9a interactors in T1D patients were also present as G9a interactors in NOD mouse splenocytes. Thus, T1D-related G9a interactors are conserved mouse-to-human. Furthermore, using the NIH Gene Expression Omnibus databases of T1D patient gene expression, the T1D clinicopathologic relevance for the genes that encode G9a interactors were validated by a multi-omics retrospective analysis. Namely, the defined panels of ChaC-identified cross-species G9a interactors exhibited T1D-characteristic mRNA co-overexpression. These results demonstrate the specificity and sensitivity of UNC0965 ChaC-MS in identifying a G9a interactors associated with T1D pathogenic Teff that reside in both human PBMCs and NOD mouse splenocytes. Strikingly, the histone methyltransferase Enhancer of Zeste homolog 2 (Ezh2) implicated as a T1D-driving histone modifier was identified as a T1D-specific G9a interactor, which demonstrates that inhibitors of G9a and Ezh2, alone or in combination, specifically target T1D-driving Teff cells.Docket No. 4210.0538WO EXAMPLE 4 Inhibitors of G9a and Ezh2 suppress diabetogenic Teff The in vivo effects of inhibiting the enzymatic activity of G9a and Ezh2 on β cell-specific T cell reactivity were assessed. Transgenic NOD mice transgenic were treated for the BDC2.5 clonotypic T cell receptor with small molecule inhibitors of G9a (UNC0642) and Ezh2 (UNC1999). The islets of 6-week-old NOD.BDC2.5 mice are heavily infiltrated with CD4+ Teff that exhibit a type-1 (IFNγ+) phenotype. Cohorts (n=3) of NOD.BDC2.5 mice were treated daily with 1 mg / kg of UNC0642 and UNC1999 inhibitors for nine days. Notably, the inhibitors reduced the number of CD4+ T cells 3-4-fold in the islets and draining pancreatic lymph nodes (PLN) versus the control group (Fig. 1A). Importantly, this effect was islet- or Teff-specific; the number of splenic CD4+ T cells was unaffected in the experimental groups (Fig.1A). This latter finding suggested that the G9a and Ezh2 inhibitors targeted recent antigen- stimulated Teff. Furthermore, G9a and Ezh2 inhibitors significantly reduced the frequency of IFNγ+ Teff that reside in the islets (Fig.1B). Consistent with this finding, inhibition of G9a and Ezh2 activity also blocked type-1 Teff differentiation in vitro. Here, naïve CD4+ T cells negatively selected by an AutoMacs from NOD mice spleen were stimulated with anti-CD3 / CD28 (1 μg / ml) and cultured under conditions to promote type-1 Teff differentiation (plus IL-12p70, IFNγ) plus / minus varying concentrations of UNC0642 or UNC1999. Inhibition of G9a and Ezh2 markedly reduced the frequency of IFNγ-expressing Teff (e.g., 3-9-fold). EXAMPLE 5 G9a and Ezh2 inhibitors suppress T1D pathogenesis- or diabetes-associated proteins. Quantitative proteomic and phosphoproteomic experiments were conducted on CD4+ T cells isolated from the spleen and pancreas of 6-week-old mice treated with inhibitor or control. Inhibitor treatment suppressed expression of major G9a- interacting translation regulators in Teff associated with T1D progression. Consistent with results demonstrating that G9a and Ezh2 treatment reduced islet T cell numbers (data not shown), T1D-characteristic overexpression of numerous proteins wasDocket No. 4210.0538WO suppressed in CD4+ T cells of inhibitor-treated NOD.BDC2.5 mice. These proteins are functionally associated with multiple pathways including lymphocyte (T cell activation / proliferation), Myc-mediated glucose metabolism in diabetes, ChREBP-β (MLXIPL)-mediated pancreatic disease pathways, and IL-6 signaling.(FIG.2). These proteomic findings clearly indicate the inhibitor specificity in suppressing pathogenic Teff cells in the context of Teff-characteristic proteins. These findings also validate the model that enzymatically active G9a coordinates T1D-related translation regulatory machinery. Thus, (1) manipulating G9a and Ezh2 activity in vivo leads to selective effects on islet and PLN CD4+ Teff numbers and proinflammatory cytokine expression and low toxicity on other organs, and (2) G9a and its interactors (e.g., represented here by Ezh2) upregulate translation mechanisms of T1D pathogenesis. Notably, G9a and Ezh2 inhibitors showed effects on the CD4+ T cells in islets or PLN but not the spleen, which suggested that antigen-stimulated Teff were selectively suppressed. REFERENCES All references listed herein including but not limited to all patents, patent applications and publications thereof, scientific journal articles, and database entries are incorporated herein by reference in their entireties to the extent that they supplement, explain, provide a background for, or teach methodology, techniques, and / or compositions employed herein. Wrobel, J.A. et al. Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors. iScience 17, 359-378 (2019). Kim, Y. et al. Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome. Nat Med 23, 213-222 (2017). Liu, C. et al. A chromatin activity-based chemoproteomic approach reveals a transcriptional repressome for gene-specific silencing. Nature communications 5, 5733 (2014).Docket No. 4210.0538WO Konze, K.D. et al. A chemical tool for in vitro and in vivo precipitation of lysine methyltransferase G9a. ChemMedChem 9, 549-53 (2014). It will be understood that various details of the presently disclosed subject matter may be changed without departing from the scope of the presently disclosed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.

Claims

Docket No. 4210.0538WO CLAIMS What is claimed is:

1. A method of treating and / or preventing Type-1 diabetes (T1D) in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof.

2. The method of claim 1, wherein administration of the inhibitor mitigates β cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells.

3. The method of claim 1 or 2, wherein inhibition of G9a and / or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive β cell autoimmunity.

4. The method of any one of claims 1 to 3, wherein β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff).

5. The method of claim 4, wherein G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation.

6. The method of claim 4 or 5, wherein targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1D progression.

7. The method of any one of claims 1 to 6, wherein the subject is suffering from T1D or susceptible to developing T1D.

8. The method of any one of claims 1 to 7, wherein the G9a inhibitor comprises a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a.

9. The method of claim 8, wherein the G9a inhibitor comprises UNC0642.

10. The method of claim 8, wherein the EZH2 inhibitor comprises UNC1999.Docket No. 4210.0538WO 11. The method of any one of claims 1 to 10, wherein the subject is co- administered both the inhibitor of G9a and the inhibitor of Ezh2.

12. The method of any one of claims 1 to 11, wherein the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier.

13. The method of any one of claims 1 to 12, wherein the subject is a human subject.

14. A method of regulating translation of proteins driving Teff-mediated β cell autoimmunity in vivo, the method comprising administering to subject a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof.

15. The method of claim 14, wherein administration of the inhibitor mitigates β cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells.

16. The method of claim 14 or 15, wherein G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive β cell autoimmunity.

17. The method of any one of claims 14 to 16, wherein β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff).

18. The method of any one of claims 14 to 17, wherein G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation.

19. The method of any one of claims 14 to 18, wherein the subject is suffering from T1D or susceptible to developing T1D.

20. The method of claim 19, wherein targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1D progression.Docket No. 4210.0538WO 21. The method of any one of claims 14 to 19, wherein the G9a inhibitor comprises a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a.

22. The method of claim 21, wherein the G9a inhibitor comprises UNC0642.

23. The method of claim 21, wherein the EZH2 inhibitor comprises UNC1999.

24. The method of any one of claims 14 to 23, wherein the subject is co- administered both the inhibitor of G9a and the inhibitor of Ezh2.

25. The method of any one of claims 14 to 24, wherein the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier.

26. The method of any one of claims 14 to 25, wherein the subject is a human subject.

27. A method of identifying a compound to treat and / or prevent Type-1 diabetes (T1D) or related condition in a subject, the method comprising identifying a compound that blocks G9a translational regulation of β cell autoimmunity.

28. The method of claim 27, wherein the compound that blocks G9a translational regulation of β cell autoimmunity does so by suppressing translation of T1D- related proteins in pathogenic effector T cells.

29. The method of claim 27 or 28, wherein the compound comprises an inhibitor of G9a, optionally a small molecule inhibitor.

30. The method of claim 27 or 28, wherein the compound comprises an inhibitor of Ezh2, optionally a small molecule inhibitor.

31. Use of a composition for treating a subject suffering from symptoms of Type- 1 diabetes (T1D) or related condition, comprising administering to the subject the composition comprising a therapeutically effective amount of an inhibitor of G9a, an inhibitor of Ezh2, and / or combinations thereof.Docket No. 4210.0538WO 32. The use of claim 31, wherein administration of the inhibitor mitigates β cell autoimmunity by suppressing translation of T1D-related proteins in pathogenic effector T cells.

33. The use of claim 31 or 32, wherein G9a inhibition or inhibition of Ezh2 reduces pancreas-infiltrating Teff that drive β cell autoimmunity.

34. The use of any one of claims 31 to 33, wherein β cell autoimmunity is substantially suppressed to thereby prevent and / or reverse T1D by targeting aberrantly activated translation mechanisms in pathogenic effector T cells (Teff).

35. The use of any one of claims 31 to 34, wherein G9a and / or Ezh2 inhibition downregulates in vivo expression of proteins regulating Teff pathogenicity, optionally proteins related to glucose metabolism in diabetes, pancreatic disease pathway, and / or T cell proliferation.

36. The use of any one of claims 31 to 35, wherein the subject is suffering from T1D or susceptible to developing T1D.

37. The use of claim 36, wherein targeting G9a-mediated translational mechanisms in autoreactive Teff prevents and / or reverses T1D progression.

38. The use of any one of claims 31 to 36, wherein the G9a inhibitor comprises a small molecule capable of reducing and / or inhibiting translational regulatory processes associated with G9a.

39. The use of claim 38, wherein the G9a inhibitor comprises UNC0642.

40. The use of claim 38, wherein the EZH2 inhibitor comprises UNC1999.

41. The use of any one of claims 31 to 40, wherein the subject is co-administered both the inhibitor of G9a and the inhibitor of Ezh2.

42. The use of any one of claims 31 to 41, wherein the inhibitor of G9a and / or Ezh2 is administered to the subject in a pharmaceutically acceptable formulation or carrier.

43. The use of any one of claims 31 to 42, wherein the subject is a human subject.

Citation Information

Patent Citations

  • Methods and compositions for expansion of stem cells and other cells

    US20150250824A1